XETRA - Delayed Quote EUR

Pfizer Inc. (PFE.DE)

26.32 -1.01 (-3.71%)

At close: November 6 at 5:35:33 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ACCESS Newswire 2d ago

MDCX

PFE
Global Hemophilia B Gene Therapy Market Report 2026 | Capitalize on 29.8% CAGR as Pfizer, CSL Behring, Bayer, and REGENXBIO Accelerate AAV Innovation

GlobeNewswire 2d ago

PFE

BAYN.DE
European Enterprises Face Growing Pressure to Turn AI Investment into Business Value, ISG Says

Business Wire 3d ago

ADEN.SW

PFE

HO.PA
Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026

GlobeNewswire 4d ago

MDCX

PFE
United Therapeutics Announces Buydown of Ralinepag Royalty

Business Wire 4d ago

UTHR

PFE
Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher

CNW Group 5d ago

NVDA

PLTR

APO
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

Business Wire 5d ago

PFE
Pfizer Appoints Cecile Guegan as Chief Financial Officer

Business Wire 5d ago

PFE
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

GlobeNewswire 9d ago

NVS

PFE

BAYN.DE
Preclinical CRO - Global Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | AI Adoption and Outsourcing Propel Revenue to USD 11.74 Billion

GlobeNewswire 10d ago

PFE
Global HER2 Targeted Therapies Market Report 2026 | Capitalize on 8.6% CAGR as Pfizer, Roche, AstraZeneca, and Daiichi Sankyo Advance ADCs and Precision Oncology

GlobeNewswire 10d ago

PFE

ROP.SW

AZN
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development

Business Wire 10d ago

PFE

Performance Overview

Return	PFE.DE	S&P 500 (^GSPC)
YTD	+33.30%	+7.76%
1-Year	+33.64%	+9.77%
3-Year	+14.81%	+68.96%

U.S. markets closed

Pfizer Inc. (PFE.DE)

Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Global Hemophilia B Gene Therapy Market Report 2026 | Capitalize on 29.8% CAGR as Pfizer, CSL Behring, Bayer, and REGENXBIO Accelerate AAV Innovation

European Enterprises Face Growing Pressure to Turn AI Investment into Business Value, ISG Says

Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026

United Therapeutics Announces Buydown of Ralinepag Royalty

Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

Pfizer Appoints Cecile Guegan as Chief Financial Officer

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

Preclinical CRO - Global Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | AI Adoption and Outsourcing Propel Revenue to USD 11.74 Billion

Global HER2 Targeted Therapies Market Report 2026 | Capitalize on 8.6% CAGR as Pfizer, Roche, AstraZeneca, and Daiichi Sankyo Advance ADCs and Precision Oncology

Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development